Skip to content

EPS (Basic) at other companies

Eli Lilly logo
Eli LillyLLY
$8.27+169%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.99-7.8%
AbbVie logo
AbbVieABBV
$0.39-45.8%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$0.24-167%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s EPS (basic)?
Apogee Therapeutics, Inc. (APGE) reported EPS (basic) of -$1.06 in Q1 2026.
How has Apogee Therapeutics, Inc.'s EPS (basic) changed year-over-year?
Apogee Therapeutics, Inc.'s EPS (basic) decreased by 11.6% year-over-year, from -$0.95 to -$1.06.
What is the long-term trend for Apogee Therapeutics, Inc.'s EPS (basic)?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s EPS (basic) has grown at a -23.0% compound annual growth rate (CAGR), from -$7.12 to -$4.22.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.